GlobeNewsWire
24 Mar 2026, 20:17 UTC · 27w ago
Verdict
Headline leans bearish. We score CORT −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) for Corcept's drug relacorilant, stating it could not reach a favorable benefit-risk assessment without further evidence of effectiveness.
So whatA CRL is a major regulatory setback that prevents drug approval, directly impacting the company's future revenue pipeline and valuation.
More negative than 99% of claims this week
A class action lawsuit has been filed against Corcept Therapeutics alleging securities fraud or unlawful business practices.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 85% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a class action lawsuit following an FDA rejection of a new drug application and a 50.4% stock price drop.
More negative than 84% of ticker scores this week
The company is the subject of a newly filed class action lawsuit.
More negative than 72% of ticker scores this week
The company is currently under investigation for potential claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
+240.7%
Price is moving against the score
$115.23 vs $33.82 close before publication (Mar 24) · not market-adjusted
CORT chart →
